AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05018624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol brief intervention
Description: At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
Study NCT05018624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol brief intervention
Description: At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
Study NCT05018624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-page health warning leaflet
Description: Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
Study NCT05018624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-page health warning leaflet
Description: Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
Study NCT05018624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular messages through Instant Messaging (IM)
Description: A total of 26 e-messages will be scheduled: once daily for the first week, 3 time/week for subsequent 4 weeks and 1 time/week for the remaining 7 weeks. The frequency will be adjusted according to IM Apps conversation and subject's requests.
Study NCT05018624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time chat-based support through IM Apps
Description: The chat-based IM support is the extension of baseline ABI and regular e-messages, which aims to provide real-time behavioral and psychosocial support to reduce or quit drinking. It will be personalized according to the subjects' characteristics (gender, drinking pattern and alcoholic drinks preferences), intention to drink and specific questions regarding drinking. Through real-time chatting (text and/or voice), drinkers can acquire information on consequences of drinking and gain social support immediately to reduce intention to drink and alcohol consumption.
Study NCT05018624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health through IM Apps
Description: After baseline, they will receive regular e-message through IM Apps with similar frequency to Intervention group with content on general health and the reminding the importance of participating in the follow-up surveys.
Study NCT05018624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong
Description: a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women
Study NCT05018624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong
Description: a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women
Study NCT05328609 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Semaine Hormonal Imbalance & The Daily
Description: All participants will undergo a menstrual cycle without intervention to establish a baseline, and then will be given the intervention (dietary supplement) for a second menstrual cycle.
Study NCT05632159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mg sulphate
Description: Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation. With extra administration of intraoperative Magnesium sulphate 30 mg /kg as loading dose over 10 min then 10 mg /kg/ has maintenance dose
Study NCT05632159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: conventional anaesthesia
Description: Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation.
Study NCT06036745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + SOX
Description: Pembrolizumab 200mg, ivdrip, q3w; Oxaliplatin 135mg/m2, ivdrip，q3w; Trastuzumab 40 mg/m2，po bid，d1\~d14，q21d. Each cycle consists of three weeks, totaling eight cycles
Study NCT05260736 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular brachial plexus block
Description: Named after the anatomical site; patients will be applied infraclavicular brachial plexus block with costoclavicular lateral, costoclavicular medial or lateral sagittal approach.
Study NCT04607668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Trilaciclib diluted in dextrose 5% in water or normal saline (sodium chloride solution 0.9%) administered by IV infusion over approximately 30 (±10) minutes no more than 4 hours prior to each Day 1 chemotherapy administration. Second dose of trilaciclib was administered on Day 2.
Study NCT04607668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose 5% in water or normal saline (sodium chloride solution 0.9%) administered by IV infusion over 30 (±10) minutes no more than 4 hours prior to each Day 1 chemotherapy administration. Second dose of placebo was administered on Day 2.
Study NCT06335329 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discussion of point-of-care ultrasound lung findings
Description: The investigator will obtain point-of-care ultrasound images to assess the lung findings in 12 lung fields. These 12 lung fields will include the standard protocol of the upper and lower halves of the anterior, lateral, and posterior chest bilaterally. Subjects' ultrasound images will be scored using a modified lung ultrasound score (LUS). Each of the 12 lung fields will be scored from 0-5, with a total score of 0-60 (noted below). The participants will watch their ultrasound being performed, looking at their lungs in real time. Then, the ultrasound findings will be discussed with the participant.~Modified LUS 0: No B-lines present~1. 1 well-defined B-line~2. 2-3 well-defined B-lines~3. >3 B-lines~4. Confluent B-lines~5. Lobar consolidation~   * C: Noted if subpleural consolidation present~  * E: Noted if pleural effusion present
Study NCT06051201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ReceptIVFity test (vaginal microbiome swab)
Description: A vaginal self-swab for determination of the vaginal microbiome is performed by the patient.~For women of European origin randomization in one of the following groups:~SDM group: Using Shared-Decision-Making according to the ReceptIVFity microbiome profile with its predicted chance of achieving a pregnancy in the current cycle.~Physician decision group: Postponing treatment until a switch to a favorable ReceptIVFity microbiome profile
Study NCT05256628 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Protected Weightbearing
Description: Patients randomized to undergo this study intervention will be instructed to be touch weightbearing for 6 weeks after surgery. They will use crutches and put no more weight on the surgical side than what it takes to crack an egg. After the 6-week mark, they will be able to bear weight.
Study NCT05866952 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography of the Chest
Description: Quantitative Computed Tomography of the chest in the inspiratory and expiratory phases will be performed to assess regional lung ventilation as well as pulmonary vascular volume and distribution
Study NCT06108232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given by IV (vein)
Study NCT06108232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99282
Description: Given by PO
Study NCT05236816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue (physical exercise)
Description: Subjects were evaluated before and after a fatiguing exercise of hip abductor muscles that consisted to repeat hip abduction with rate and range of motion until a target decrease of force is attempt
Study NCT06039579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280
Description: VH4004280 will be administered.
Study NCT06039579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4011499
Description: VH4011499 will be administered.
Study NCT06039579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VH4004280 Matching Placebo
Description: VH4004280 matching placebo will be administered.
Study NCT06039579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VH4011499 Matching Placebo
Description: VH4011499 matching placebo will be administered.
Study NCT05561920 — intervention group
Intervention type: DEVICE
Intervention: High - speed video endoscopy (HSV)
Description: Describe anatomical and morphological characteristics o phonatory movement of PEM in laryngectomy patients
Study NCT05561920 — intervention group
Intervention type: DEVICE
Intervention: Acoustic voice analysis
Description: acoustic program (lingWAVES - Voice and speech analyser) - measuring the values of acoustic parameters in voice recordings
Study NCT05561920 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaire
Description: Filling out questionnaires
Study NCT06271512 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is non-interventional study.
Study NCT06359158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital stethoscope use
Description: In this interventional study, 84 medical students were randomly allocated to an intervention group utilizing a novel digital stethoscope curriculum or a control group receiving traditional instruction. The intervention leveraged digital stethoscopes, enabling visualization and analysis of recorded breath sounds. Pre- and post-assessments evaluated respiratory
Study NCT02403505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA protein antigen plus BCG Vaccine Mix for percutaneous use
Description: * By the percutaneous route with the multiple puncture device~* CEA protein antigen 0.05 mg plus BCG Organism 50 MG Mix
Study NCT05935735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Insomnia (BBTI)
Description: 4 in-person sessions; 1 individual and 3 group sessions
Study NCT06387264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Adhesive
Description: Medical Adhesive (produced by Beijing Compont Medical Devices Co., Ltd.) For varicose veins in the main saphenous vein, use 0.1 ml glue for every 3 cm of blood vessels.
Study NCT06387264 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClosureFast Endovenous Radiofrequency Ablation(RFA) Catheter
Description: ClosureFast Endovenous Radiofrequency Ablation (RFA) Catheter (produced by America Medtronic Inc.) The ClosureFast catheter precisely heats a 7 cm vein segment in one 20-second interval.
Study NCT06245941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ05105 tablets
Description: TQ05105 is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor
Study NCT06245941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3909 tablets
Description: TQB3909 is an inhibitor targeting B-cell lymphoma-2 (BCL-2) protein.
Study NCT06289101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text4FATHER
Description: Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of age.
Study NCT05621070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS002
Description: JS002 will be administered per auto-injector. Participants will receive JS002 every 2 weeks subcutaneously.
Study NCT05621070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JS002
Description: JS002 will be administered per auto-injector. Participants will receive JS002 every 4 weeks subcutaneously.
Study NCT05621070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered per auto-injector. Participants will receive placebo every 2 weeks subcutaneously.
Study NCT05621070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered per auto-injector. Participants will receive placebo every 4 weeks subcutaneously.
Study NCT06366217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MydCombi Device
Description: ophthalmic spray
Study NCT06366217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MydCombi Drug
Description: Tropicamide 1% and phenylephrine HCl 2.5%
Study NCT05616624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Description: -Given 60 minutes (+/- 15 minutes) prior to docetaxel
Study NCT05616624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: -Given over the course of 90 minutes (+/- 10 minutes)
Study NCT05616624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: -Given over the course of 60 minutes (+/- 10 minutes)
Study NCT06513858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communal Drumming
Description: Communal drumming
Study NCT06513858 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communal drumming recordings
Description: Recordings of drumming taken from the music made during a previous component of the study
Study NCT06513858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communal drumming recordings
Description: Recordings of drumming taken from the music made during a previous component of the study
Study NCT05156047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label pitolisant
Description: Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant.
Study NCT05156047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double-blind placebo
Description: Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
Study NCT05156047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Double-blind pitolisant
Description: Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant.
Study NCT05884307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trans Care Web App
Description: an educational and interactive website designed to improve coping strategies of TNB individuals
Study NCT06221280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block
Description: Group E: While performing the erector spina plan block; Patients are placed in the lateral decubitus position, aseptic conditions are provided, the spinous process in the midline is determined under ultrasonography guidance, and the transverse process is determined 3 cm laterally from the T11 level. 100 mm 22G block needle erector.~Group T: The lumbar petit region will be determined and placed on the lateral abdominal wall at the mid-axillary line, between the iliac crest and the lower costal arch, via a linear probe (12-15 MHz probe). After determining the internal oblique muscle as the thickest muscle and the transversus abdominis muscle as the thinnest muscle, a 100 mm 22 G needle will be placed in the same plane as the USG probe (in-plane or long axis technique). The progress of the needle will be observed on ultrasound along with the facial click sensation. After the second click sensation is felt between the internal oblique and transversalis fascia.
Study NCT04851691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHR CDS
Description: When a clinician initiates a new antipsychotic prescription for a patient with dementia, a three-pronged electronic health record clinical decision support tool pops up: (1) Alerting clinicians that antipsychotic prescriptions increase patient mortality; (2) Offering non-pharmacological behavioral resources for caregivers via a link to the IDEA! strategy resources on how caregivers can best manage a patient's behavioral disturbance non-pharmacologically, which will be available in the EHR to include in the patient's after visit summary; and (3) Defaulting prescriptions to a low supply of pills in to order to minimize harm. In addition, the PI will email all providers randomized to the intervention arm in order to make them aware of the components of this intervention and its motivation.
Study NCT04851691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Patients will receive usual care from their physicians.
Study NCT06296849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive Treatment (FIT)
Description: In the present study, the investigators will provide financial incentives of $200 for biochemically verified abstinence at each of three time points (1 month, 3 month, and 6 month) following baseline. Additionally, the investigators will provide a bonus of $200 for participants who demonstrate abstinence at each of the time points. This incentive value is consistent with recent research using macro-level financial incentives and incorporates both short-term and long-term incentives to shape behavior.
Study NCT05414500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Administered IV
Study NCT05414500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Administered IV
Study NCT05880979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engaging Together for Healthy Relationships
Description: A comprehensive parent-adolescent dating violence prevention intervention designed to be provider delivered within the context of a pediatric well-child visit
Study NCT05880979 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular well child care
Description: Participants will receive their regularly scheduled well-child care
Study NCT06513910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Participants in dyads will be positioned across from each other while listening to various types of music (i.e. music that is harmonically-intact and music in which the harmonic content has been randomly scrambled).
Study NCT06235515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation program
Description: conventional treatment (hotpack and TENS and exercise)
Study NCT06235515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: virtual reality treatment
Study NCT05315414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrimeTaper EV implant
Description: Tapered dental implant developed by Dentsply Sirona
Study NCT05516537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidelines for Exercise in Multiple Sclerosis (GEMS)
Description: Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training.
Study NCT05516537 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: FLEX Stretching and Toning Program
Description: Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training.
Study NCT04986072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: Half of participants will receive Intravenous Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours.
Study NCT04986072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Dextrose solution
Description: Half of participants will receive intravenous 5% Dextrose solution for 4 hours.
Study NCT04956796 — intervention group
Intervention type: BEHAVIORAL
Intervention: Airway Video Library Training
Description: A video airway library consisting of real-life clinical videos of laryngoscopy and endotracheal intubation was developed by the study investigators. This library consists of video clips of normal and easy airways, pediatric airways as well as pathological or difficult airways that is devoid of patient identifying data. The participants of the study group will be exposed to the video library by two learning sessions. Each learning session consists of 1 hour of interactive \& immersive learning of 30 airway videos. At the end of the session, the participants will be oriented to the airway and identify key airway structures, learn to troubleshoot and navigate difficult anatomy, optimize visualization, and use accessory airway equipment.
Study NCT04956796 — intervention group
Intervention type: BEHAVIORAL
Intervention: Conventional Airway Training
Description: The endotracheal intubation training Anesthesiology students currently receive routinely as part of their education.
Study NCT04784325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw through TAP II
Description: Two self-administered blood draws through TAP II device
Study NCT04784325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw through ADx cardT
Description: One self-administered ADx card blood draw